Gene · 4883
Papers1,657
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,657
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NPR3 promotes colorectal cancer cell proliferation, migration, invasion, and chemotherapy resistance. | Biochim Biophys Acta Gen Subj | 2026 | 41380984 | PubTator, text mining | PubMed |
| Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology. | Cardiovasc Drugs Ther | 2026 | 41369834 | PubTator, text mining | PubMed |
| Construction of a survival prognosis model for epithelial-mesenchymal transition-related genes in gastric cancer. | Eur J Med Res | 2025 | 41372983 | PubTator, text mining | PubMed |
| Dual-source 17/25-Level ANPC inverter with low stress on devices and reduced part count suitable for hybrid energy systems. | Sci Rep | 2025 | 41083596 | PubTator, text mining | PubMed |
| Inhibition of vascular intimal hyperplasia by the myokine Musclin: the role of NPR3/raptor/mTORC1-mediated glycolysis and phenotypic switching of VSMCs. | Acta Biochim Biophys Sin (Shanghai) | 2025 | 41074587 | PubTator, text mining | PubMed |
| Necesidad de ajustar al IMC los valores límite de los péptidos natriuréticos para un diagnóstico más personalizado de la insuficiencia cardíaca. | Adv Lab Med | 2025 | 40977826 | PubTator, text mining | PubMed |
| The pivotal role of TGF-β/Smad pathway in fibrosis pathogenesis and treatment. | Front Oncol | 2025 | 40969268 | PubTator, text mining | PubMed |
| Targeted degradation of NPR3 confers broad-spectrum resistance in wheat. | Mol Plant | 2025 | 40913311 | PubTator, text mining | PubMed |
| Salicylic acid regulates biosynthesis of floral fragrance (E)-β-farnesene via NPR3-WRKY1 module in chrysanthemum. | Mol Hortic | 2025 | 40908482 | PubTator, text mining | PubMed |
| Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial. | Sci Adv | 2025 | 40880481 | PubTator, text mining | PubMed |
| The role and clinical value of natriuretic peptide receptor family in malignant tumor. | Cell Death Discov | 2025 | 40877221 | PubTator, text mining | PubMed |
| A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system. | Front Pharmacol | 2025 | 40843382 | PubTator, text mining | PubMed |
| Salvaged Signals, Scarred Filters: Podocyte NPRC in Diabetic Kidney Disease. | Circ Res | 2025 | 40743306 | PubTator, text mining | PubMed |
| A Pan-Cancer Analysis of Natriuretic Peptide Receptor 3 (NPR3) with Clinical Cohort and in vitro Validation. | J Inflamm Res | 2025 | 40740975 | PubTator, text mining | PubMed |
| IGF2BP3 promotes osteosarcoma malignancy through stabilization of m6A-modified UBE4AmRNA, which involves promotion of NPR3 ubiquitination and degradation. | Physiol Int | 2025 | 40674149 | PubTator, text mining | PubMed |
| Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. | Drugs | 2025 | 40571893 | PubTator, text mining | PubMed |
| Optimizing C-Type Natriuretic Peptide and Receptor Expression Analysis with Droplet Digital™ PCR: Advancing Biomarker Discovery for Brugada Syndrome? | Biomolecules | 2025 | 40563432 | PubTator, text mining | PubMed |
| Associations of Genetically Predicted NPR3 and NPR2 Perturbation and Preeclampsia Risk: A Two-Sample Mendelian Randomization Analysis. | Int J Hypertens | 2025 | 40406480 | PubTator, text mining | PubMed |
| ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function. | Eur Heart J Suppl | 2025 | 40385467 | PubTator, text mining | PubMed |
| [Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation]. | Korean J Gastroenterol | 2025 | 40276827 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4883/papers?page=2